Booklet helps to improve patient knowledge of totally implantable access ports
the ONA take:
A well-designed booklet with attention to both scientific content and communication techniques is useful in improving patients' knowledge about totally implantable access ports (TIAPs) and reducing anxiety, according to a recent study published online ahead of print in the journal Supportive Care in Cancer.
It is recommended that patients are provided written information about TIAPs during the pre-implantation period to decrease anxiety and improve recall of information; however, no study has evaluated the effectiveness of information about TIAP given to patients.
For the study, researchers enrolled 105 patients with cancer who were getting TIAP implanted. Of those, 34 were randomly assigned to receive only an information booklet, 34 received the booklet with answers to clarification questions, and 37 received routine care.
Results showed that all three interventions provided resulted in a decrease in patients' anxiety immediately after TIAP implantation and at 3 months. Adding answers to clarification questions did not improve anxiety or patient knowledge.
A well-designed booklet is useful in improving patients' knowledge about totally implantable access ports and reducing anxiety.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|